Serum hepatic enzyme manifestations in patients with severe acute respiratory syndrome: Retrospective analysis
Open Access
- 1 January 2004
- journal article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 10 (11), 1652-1655
- https://doi.org/10.3748/wjg.v10.i11.1652
Abstract
AIM: To evaluate the hepatic function in patients with severe acute respiratory syndrome (SARS) and possible causes of hepatic disorder in these patients. METHODS: One hundred and eighty-two patients with SARS were employed in a retrospective study that investigated hepatic dysfunction. Liver alanine aminotransferase (ALT), aspartate aminotransferase (AST) and lactic dehydrogenase (LDH) were analyzed in these patients. Patients with different hospital treatments were further investigated. RESULTS: Of the 182 patients, 128 (70.3%) had abnormal ALT activity, 57 (31.3%) had abnormal AST activity and 87 (47.8%) had abnormal LDH activity. The peak of elevated hepatic enzyme activities occurred between the sixth day and the tenth day after the first day of reported fever. Of the 182 patients, 160 (87.9%) had been treated with antibiotics, 137 (75.2%) with Ribavirin, and 115 (63.2%) with methylpredisolone. There was no statistically significant correlation between the duration of Ribavirin treatement and hepatic dysfunction. CONCLUSION: Abnormal liver functions were common in patients with SARS and could be associated with virus replication in the liver.Keywords
This publication has 19 references indexed in Scilit:
- Newly discovered coronavirus as the primary cause of severe acute respiratory syndromeThe Lancet, 2003
- SARS treatment: experience from a team in Guangdong, China.2003
- Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory SyndromeNew England Journal of Medicine, 2003
- Identification of Severe Acute Respiratory Syndrome in CanadaNew England Journal of Medicine, 2003
- Coronavirus as a possible cause of severe acute respiratory syndromeThe Lancet, 2003
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis CNew England Journal of Medicine, 2003
- Ribavirin inhibits DNA, RNA, and protein synthesis in PHA‐stimulated human peripheral blood mononuclear cells: Possible explanation for therapeutic efficacy in patients with chronic HCV infectionJournal of Medical Virology, 2002
- Implications of high RNA virus mutation rates: lethal mutagenesis and the antiviral drug ribavirinMicrobes and Infection, 2002
- [Prospective study of combination of interferon-alpha with ribavirin for treatment of chronic hepatitis C in children].2001
- Aerosolized Ribavirin Treatment of Infants with Respiratory Syncytial Viral InfectionNew England Journal of Medicine, 1983